PROGRAM DESCRIPTION

This case-based CME/CPE/CNE activity is focused on addressing causes of treatment failure in serious fungal infections to improve patient outcomes. Using a multidisciplinary approach, the faculty will address inadequate testing, antifungal resistance, adherence issues, source control, and pharmacologic issues, including inadequate use of therapeutic drug monitoring. The cases will span resistant dermatophytes, coccidioidomycosis, candidemia, and an invasive mold infection.

CME/CE Information

Title: Treatment Failure in Mycology: Addressing the Root Cause

Release Date: 10/10/2023
Expiration Date: 10/9/2024
Estimated Time to Complete the Activity: 2 hrs
Media: Interactive, text-based activity

Learning Objectives

Upon completing this activity, the participant should be better able to:

• Evaluate potential causes of treatment failure with antifungal therapy
• Optimize the pharmacology of antifungal therapies, with a particular eye to therapeutic drug monitoring
• Select appropriate antifungal therapy for patients who have failed first-line therapy
• Educate patients about antifungal resistance, adherence issues, and pharmacologic challenges that can lead to antifungal treatment failure
• Work as an interdisciplinary team to identify and remedy causes of antifungal treatment failure

Target Audience

This activity is directed to physicians with specialties in infectious diseases, pulmonary/critical care medicine, and pathology/laboratory medicine as well as other health care providers who care for patients at risk for or diagnosed with invasive fungal infections.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM); Terranova Medica, LLC; and the Mycoses Study Group Education and Research Consortium (MSGERC), Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hour. Designated for 1 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number JA4008162-9999-23-219-H01-P
Type of Activity: Knowledge

Interprofessional Continuing Education

This activity was planned by and for the health care team, and learners will receive 2.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. All potential conflicts have been mitigated.

Faculty Disclosures

Peter G. Pappas, MD, FACP RESEARCH SUPPORT: Melinta, Astellas, Scynexis
CONSULTANT: F2G, Melinta, Matinas, Scynexis

Jeremy Gold, MD, MS NOTHING TO DISCLOSE

James S. Lewis, II, PharmD, FIDSA CONSULANT: Merck, Cidara, SeLux

Meghan Lyman, MD NOTHING TO DISCLOSE

Rob Purdie CONSULTANT: Clinical Outcome Solutions

Dallas Smith, PharmD NOTHING TO DISCLOSE

Mitsuru Toda, MS, PhD NOTHING TO DISCLOSE

Jo-Anne Young, MD RESEARCH SUPPORT: F2G, Pulmocide, Scynexis
CONSULTANT: AlloVir

Managers and Planning Committee Disclosures

Lisa A. Tushla, PhD, H(ASCP) of Terranova Medica, LLC, discloses research support from Bristol Myers Squibb and Novartis. The PIM planners have nothing to disclose.

Method of Participation and Request for Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. Register and complete all the sections
2. Complete all the online Posttest sections with a score of 75% or better
3. Once you complete the Posttest, a link to the evaluation on CME University will be unlocked
4. Upon completion of the evaluation, you will receive an immediate CME/CE Certificate to download and/or print for your files

For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Media

Internet

Computer System Requirements

To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).

Privacy Policy

Terranova Medica, LLC, and PIM are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information. Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
Terranova Medica, LLC, and PIM do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

There is no charge for this activity.

Jointly provided by Postgraduate Institute for Medicine; Terranova Medica, LLC; and the Mycoses Study Group Education & Research Consortium.

This educational initiative was funded in part by a cooperative agreement with the Centers for Disease Control and Prevention (CDC-RFA-CK20-2003) to the University of Alabama at Birmingham. The University of Alabama at Birmingham is collaborating with the Mycoses Study Group Education & Research Consortium and Terranova Medica, LLC, on this initiative. The Centers for Disease Control and Prevention is an agency within the Department of Health and Human Services (HHS). The contents of this resource center do not necessarily represent the policy of CDC or HHS and should not be considered an endorsement by the Federal Government.

For further information, contact Tom Davis by telephone (877-276-4523), or by email [email protected].

If you have any questions regarding the CME/CPE/CNE certification for this activity, please contact Postgraduate Institute for Medicine at: [email protected] or (303) 799-1930.

Copyright © 2023 PIM, MSGERC, and Terranova Medica.